The Claim
The CaMKK2 inhibitor STO-609 inhibits contraction-stimulated glucose uptake in mouse skeletal muscle through off-target inhibition of AMPK and other kinases, and these effects are replicated by an inactive structural analog of STO-609.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
STO-609, a compound used to block CaMKK2, reduces glucose uptake in mouse skeletal muscle during contraction because it directly blocks AMPK and other kinases, and a chemically similar but inactive version of STO-609 produces the same effect.
See the scientific wording
The previously used CaMKK2 inhibitor STO-609 inhibits contraction-stimulated glucose uptake in mouse skeletal muscle through off-target effects, as it directly inhibits AMPK and other kinases, and its effects are replicated by an inactive structural analog.
A chemical compound called STO-609 stops muscle cells from taking up sugar during exercise not by targeting the protein it was designed for, but by directly blocking other proteins that control sugar transport. Even a version of this compound that cannot block the original target still stops sugar uptake, proving the effect comes from unintended interference with kinases that regulate glucose movement into the cell.
What the research says
1 studyScientists thought a drug called STO-609 worked by blocking a protein called CaMKK2 to reduce sugar uptake in muscles during exercise. But they found that even a fake version of the drug — that can’t block CaMKK2 — does the same thing. So the drug must be messing with other proteins instead.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.